October 2022

Pharmacist involvement in identifying causes and treatment approaches is essential, as BCC can be a result of prior radiation therapy.

The agent is representative of a new class of drug, ImmTAC.

The FDA-approved, targeted radiopharmaceutical agent can contribute to a patient’s cumulative radiation exposure.

Research indicates quadruplet regimens may be a viable option for this disease.

Opportunities for further optimization of CML management remain.

Eliminating paper prescriptions allows for greater legibility, security, trackability for pharmacists and providers.

New agents can offer a more tailored approach to therapy selection.

Oncology pharmacists participate significantly in conversations, research, and publications of that research.

October is Breast Cancer Awareness Month.

Eliminating paper prescriptions allows for greater legibility, security, trackability for pharmacists, providers.